FDA Update

December 2011
Pharmaceutical Representative;Dec2011, Vol. 41 Issue 12, p11
The article offers updates related to the pharmaceutical industry in the U.S. The Food and Drug Administration (FDA) has approved drugs for diseases including late-stage metastatic melanoma and Hodgkins lymphoma in the U.S. in fiscal year 2011. The drug Eylea which is being marketed by Regeneration Pharmaceuticals to treat patients with wet age-related macular degeneration has been approved by the FDA. FDA Commissioner Margaret Hamburg has conducted a press conference on Genetech's Avastin drug.


Related Articles

  • COMMISSIONER MARGARET HAMBURG: Change Agent. Wechsler, Jill // Pharmaceutical Executive;Dec2009, Vol. 29 Issue 12, p46 

    The article focuses on the priorities and policies of Margaret Hamburg as commissioner of the U.S. Food and Drug Administration (FDA). She mentions the need for the FDA to fully comprehend the science behind new product development and research. She also plans to release guidelines on biomarker...

  • FDA chief sees 2014 as milestone year for new drug approvals.  // Chain Drug Review;1/5/2015, Vol. 37 Issue 1, p79 

    The article reports on the views of U.S. Food and Drug Administration Commissioner Margaret Hamburg that 2014 was a strong year in terms of novel drug approvals that inclues molecular entities and therapeutic biologics.

  • FDA Gets a New Look. Wechsler, Jill // Pharmaceutical Representative;Dec2011, Vol. 41 Issue 12, p26 

    The article focuses on the developments of the Food and Drug Administration (FDA) in the U.S. It states that the agency has been under pressure to encourage medical product development, monitor global supply chain, and accomplish resources. FDA which is being commissioned by Margaret Hamburg has...

  • FDA Commissioner Hamburg builds agency's capabilities for bringing new therapies to patients.  // Formulary;Feb2010, Vol. 45 Issue 2, p69 

    The article discusses the Food and Drug Administration's (FDA) Commissioner Margaret Hamburg's efforts to make new drug therapies and medical products available to patients while also ensuring their safety and efficacy. Hamburg has advocated for greater transparency at the FDA with respect to...

  • FDA Enforcement Actions in 2009. Messplay, Gary C.; Heisey, Colleen // Contract Pharma;Jan/Feb2010, Vol. 12 Issue 1, p18 

    The article reports on the major actions of Food and Drug Administration (FDA) in 2009 under the direction of physician Margaret Hamburg in the U.S. It mentions the 26 new drug applications (NDA) approved by FDA and the 31 new black box warnings to previously approved pharmaceutical products. It...

  • Zone in on: Regulation. Drakulich, Angie // Pharmaceutical Technology;Oct2010, Vol. 34 Issue 10, p29 

    The article reports on the call of Food and Drug Administration Commissioner Margaret A. Hamburg to enact user fees for the generic-drug sector in the U.S. It notes that the increase in abbreviated new drug applications (ANDAs) growth may strain the agency's review system. It states that the...

  • FDA Keeps Up the Pace on New Medicine Approvals. Winter, Peter // BioWorld Today;12/7/2012, Vol. 23 Issue 237, p1 

    The article focuses on the report issued by the U.S. Food and Drug Administration (FDA) titled "Innovative Drug Approvals for FY 2012." According to FDA Commissioner Margaret Hamburg's blog, most of the medicines were approved within its target review date. There are continued efforts by the...

  • FDA approves final ER/LA opioid analgesic REMS. Yap, Diana // Pharmacy Today;Aug2012, Vol. 18 Issue 8, p60 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) to the final Risk Evaluation and Mitigation Strategy (REMS) on July 9, 2012. FDA Commissioner Margaret Hamburg mentions that the goal of the agency with REMS is to ensure that health care professionals have the...

  • Monograph Makeover Requires Industry Input. Russo, Karen; Dressman, Shawn // Pharmaceutical Technology;May2011, Vol. 35 Issue 5, p90 

    The article focuses on the project of the U.S. Pharmacopeial Convention (USP) which aims to improve the monograph of drug standards. It states that the Food and Drug Administration (FDA) and the Consumer Healthcare Products Association (CHPA) will collaborate with USP for the project. It...


Read the Article


Sign out of this library

Other Topics